Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Phase 1 Terminated 16 enrolled Medical College of Wisconsin

Non-randomizedSequentialOpen-labelTreatment

This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	75 mg/m2	Intravenous
Subject	Pevonedistat	Small molecule	10 mg/m2	Intravenous
Subject	Pevonedistat	Small molecule	15 mg/m2	Intravenous
Subject	Pevonedistat	Small molecule	20 mg/m2	Intravenous
Subject	Venetoclax	Small molecule	400 mg	Oral